March 25, 2020

NS Pharma Announces Marketing Authorization in Japan of VILTEPSO® for the Treatment of Duchenne

Good news out of Japan! NS Pharma, Inc., announced that their parent company, Nippon Shinyaku Co., Ltd., has received approval for viltolarsen in Japan for people with Duchenne amenable to exon 53 skipping therapy. Viltolarsen…

Learn More

March 23, 2020

NS Pharma Shares Community Letter Regarding COVID-19

NS Pharma, Inc. has shared an update with the community responding to questions about how COVID-19 may be affecting ongoing studies of viltolarsen, the recently launched Expanded Access Program (EAP) and review of the viltolarsen…

Learn More

March 9, 2020

NS Pharma Announces Launch of Expanded Access Program for Viltolarsen

NS Pharma, Inc. has announced the launch of the viltolarsen Expanded Access Program in the United States for patients with Duchenne muscular dystrophy who are amenable to exon 53 skipping therapy and meet other eligibility…

Learn More

February 10, 2020

NS Pharma Announces NDA Accepted for Filing by the FDA for Antisense Oligonucleotide Viltolarsen

PPMD is thrilled to learn from Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. that the FDA has filed a New Drug Application (NDA) for their antisense oligonucleotide drug NS-065/NCNP-01 (viltolarsen). Viltolarsen is a drug…

Learn More

November 26, 2019

WATCH: NS Pharma Provides Viltolarsen Update – Webinar Recording

On November 20, 2019, NS Pharma joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of its investigational drug, viltolarsen (NS-065/NCNP-01), including its mechanism of action and regulatory status….

Learn More

November 4, 2019

End Duchenne Tour Recap: Memphis, TN

PPMD’s End Duchenne Tour made a stop in Memphis, TN on Saturday, October 26. We were joined by over 60 people,  including families, an amazing group of volunteers in our kids room, six members of…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 3, 2019

2019 World Muscle Society Update – Day 1

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 2, 2019

NS Pharma Completes Rolling NDA Submission to FDA for NS-065/NCNP-01 (viltolarsen)

We are pleased to learn that NS Pharma has completed the submission of its rolling New Drug Application (NDA) to the FDA for NS-065/NCNP-01 (viltolarsen), which is under development for the treatment of Duchenne amenable…

Learn More

September 24, 2019

End Duchenne Tour Recap: Wilmington, Delaware

PPMD’s End Duchenne Tour made a stop in Wilmington, Delaware on September 14. We were joined by over 100 people, including 30 families, 20 healthcare professionals and researchers, 15 industry partners, and 5 members of…

Learn More